Pentagon to Offer Plan to Store Eggs and Sperm to Retain Young Troops
By Michael S. Schmidt,
The New York Times
| 02. 03. 2016
Untitled Document
WASHINGTON — Defense Secretary Ashton B. Carter believes he has come up with a way to help the Pentagon retain troops: freezing sperm and eggs.
As part of an initiative to make military service more appealing and family friendly, Mr. Carter has created a pilot program that will pay for troops to have their reproductive cells preserved.
The goal is to give those in uniform the peace of mind that if they are hurt on the battlefield — hundreds of veterans suffered injuries to their reproductive organs in Iraq and Afghanistan — they would still be able to have children.
The program is also meant to encourage women to stay in the military during their 20s and 30s, a time when many leave after giving birth. By freezing their eggs, they will have the flexibility to remain deployed overseas or otherwise pursue their careers and put off having children.
Women who reach 10 years of service — what Mr. Carter called “their peak years for starting a family” — have a retention rate that is 30 percent lower...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
